Bilaketaren emaitzak - Wasserman, Scott

Development and preliminary validation of a Function IndeX for Trauma (FIX-IT) nork Bhandari, Mohit, Wasserman, Scott M., Yurgin, Nicole, Petrisor, Brad, Sprague, Sheila, Dent, Ricardo E.

Testu osoa Testu osoa Testu osoa

Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia nork Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P., Doshi, Sameer

Testu osoa Testu osoa Testu osoa

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism nork Chan, Dick C., Watts, Gerald F., Somaratne, Ransi, Wasserman, Scott M., Scott, Rob, Barrett, P. Hugh R.

Testu osoa Testu osoa Testu osoa

Effect of evolocumab on cholesterol synthesis and absorption nork Peach, Matthew, Xu, Ren, Fitzpatrick, Dan, Hamilton, Lisa, Somaratne, Ransi, Scott, Robert, Wasserman, Scott M., Djedjos, C. Stephen

Testu osoa Testu osoa Testu osoa

Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab nork Desai, Nihar R., Giugliano, Robert P., Wasserman, Scott M., Gibbs, John P., Liu, Thomas, Scott, Rob, Sabatine, Marc S.

Testu osoa Testu osoa Testu osoa

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor nork Kasichayanula, Sreeneeranj, Grover, Anita, Emery, Maurice G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P.

Testu osoa Testu osoa Testu osoa

Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol‐Lowering Therap... nork Chan, Dick C., Watts, Gerald F., Coll, Blai, Wasserman, Scott M., Marcovina, Santica M., Barrett, P. Hugh R.

Testu osoa Testu osoa Testu osoa

Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hyperc... nork Cho, Leslie, Rocco, Michael, Colquhoun, David, Sullivan, David, Rosenson, Robert S., Dent, Ricardo, Xue, Allen, Scott, Rob, Wasserman, Scott M, Stroes, Erik

Testu osoa Testu osoa Testu osoa

Consistent LDL‐C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies nork Stroes, Erik, Robinson, Jennifer G., Raal, Frederick J., Dufour, Robert, Sullivan, David, Kassahun, Helina, Ma, Yuhui, Wasserman, Scott M., Koren, Michael J.

Testu osoa Testu osoa Testu osoa

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Par... nork Kohli, Payal, Ganz, Peter, Ma, Yifei, Scherzer, Rebecca, Hur, Sophia, Weigel, Bernard, Grunfeld, Carl, Deeks, Steven, Wasserman, Scott, Scott, Rob, Hsue, Priscilla Y.

Testu osoa Testu osoa Testu osoa

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety nork Lee, Edward, Gibbs, John P., Emery, Maurice G., Block, Geoffrey, Wasserman, Scott M., Hamilton, Lisa, Kasichayanula, Sreeneeranj, Hanafin, Patrick, Somaratne, Ransi, Egbuna, Ogo

Testu osoa Testu osoa Testu osoa

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexi... nork Stiekema, Lotte C A, Stroes, Erik S G, Verweij, Simone L, Kassahun, Helina, Chen, Lisa, Wasserman, Scott M, Sabatine, Marc S, Mani, Venkatesh, Fayad, Zahi A

Testu osoa Testu osoa Testu osoa

Evaluation of Evolocumab (AMG 145), a Fully Human Anti‐PCSK9 IgG2 Monoclonal Antibody, in Subjects With Hepatic Impairment nork Gibbs, John P., Slatter, J. Greg, Egbuna, Ogo, Geller, Michelle, Hamilton, Lisa, Dias, Clapton S., Xu, Ren Y., Johnson, Jessica, Wasserman, Scott M., Emery, Maurice G.

Testu osoa Testu osoa Testu osoa

Impact of Target‐Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) nork Gibbs, John P., Doshi, Sameer, Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Dodds, Michael G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Blom, Dirk

Testu osoa Testu osoa Testu osoa

The role of Hath6, a newly identified shear-stress-responsive transcription factor, in endothelial cell differentiation and function nork Fang, Fang, Wasserman, Scott M., Torres-Vazquez, Jesus, Weinstein, Brant, Cao, Feng, Li, Zongjin, Wilson, Kitchener D., Yue, Wen, Wu, Joseph C., Xie, Xiaoyan, Pei, Xuetao

Testu osoa Testu osoa Testu osoa

Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data nork Qamar, Arman, Giugliano, Robert P., Keech, Anthony C., Kuder, Julia F., Murphy, Sabina A., Kurtz, Christopher E., Wasserman, Scott M., Sever, Peter S., Pedersen, Terje R., Sabatine, Marc S.

Testu osoa Testu osoa Testu osoa

Design and Rationale of the LAPLACE‐TIMI 57 Trial: A Phase II, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 i... nork Kohli, Payal, Desai, Nihar R., Giugliano, Robert P., Kim, Jae B., Somaratne, Ransi, Huang, Fannie, Knusel, Beat, McDonald, Shannon, Abrahamsen, Timothy, Wasserman, Scott M., Scott, Robert, Sabatine, Marc S.

Testu osoa Testu osoa Testu osoa

Rationale and Design of LAPLACE‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hy... nork Robinson, Jennifer G., Rogers, William J., Nedergaard, Bettina S., Fialkow, Jonathan, Neutel, Joel M., Ramstad, David, Somaratne, Ransi, Legg, Jason C., Nelson, Patric, Scott, Rob, Wasserman, Scott M., Weiss, Robert

Testu osoa Testu osoa Testu osoa

Design and rationale of the EBBINGHAUS trial: A phase 3, double‐blind, placebo‐controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients wi... nork Giugliano, Robert P., Mach, Francois, Zavitz, Kenton, Kurtz, Christopher, Schneider, Jingjing, Wang, Huei, Keech, Anthony, Pedersen, Terje R., Sabatine, Marc S., Sever, Peter S., Honarpour, Narimon, Wasserman, Scott M., Ott, Brian R.

Testu osoa Testu osoa Testu osoa

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LA... nork Giugliano, Robert P, Desai, Nihar R, Kohli, Payal, Rogers, William J, Somaratne, Ransi, Huang, Fannie, Liu, Thomas, Mohanavelu, Satishkumar, Hoffman, Elaine B, McDonald, Shannon T, Abrahamsen, Timothy E, Wasserman, Scott M, Scott, Robert, Sabatine, Marc S

Testu osoa Testu osoa Testu osoa